CompletedNCT00195845
Galantamine for cognitive difficulties in people with stable bipolarity
About this title
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Read the official source — NCT00195845This study assessed thinking abilities.
Medication studyAges 18–60United States
Understand this study
What did researchers investigate?
This study assessed thinking abilities.
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Cambridge Health Alliance
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00195845
- Official title
Show the full official title
A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study assessed thinking abilities.
Who is behind this study?
The study sponsor is Cambridge Health Alliance.
Did this study involve medication?
Yes. The study involved medication, including Galantamine and Placebos.
Who was this study for?
Listed age limits: 18 years to 60 years.
